Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
99 hedge funds and large institutions have $169M invested in Catalyst Pharmaceutical in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 22 reducing their positions, and 15 closing their positions.
271% more call options, than puts
Call options by funds: $293K | Put options by funds: $79K
114% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 22
29% more capital invested
Capital invested by funds: $131M → $169M (+$38.4M)
1% more funds holding
Funds holding: 98 → 99 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0.54% less ownership
Funds ownership: 53.36% → 52.82% (-0.54%)
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$5.16M |
| 2 |
BlackRock
New York
|
+$4.13M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$3.95M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$3.19M |
| 5 |
Morgan Stanley
New York
|
+$1.69M |
Top Sellers
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.44M |
| 2 |
Renaissance Technologies
New York
|
-$3.77M |
| 3 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$3.22M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$2.3M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$2.24M |
CPRX Hedge Fund Activity: Q2 2018 in Review
99 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2018, worth a combined $169M — up 29% from $131M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CPRX positions and 15 closed out — a net gain of 1 holder — while 47 added to existing stakes and 22 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $5.16M. The largest seller was Great Point Partners, exiting entirely with an estimated $6.44M sold.
- 99 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2018, up from 98 in Q1 2018.
- Funds reported $169M of Catalyst Pharmaceutical stock for Q2 2018, up 29% quarter-over-quarter.
- 16 funds opened new Catalyst Pharmaceutical positions in Q2 2018 and 15 closed out, a net change of +1 holder.
- The largest Catalyst Pharmaceutical buyer in Q2 2018 was Armistice Capital, an estimated $5.16M added.
- The largest Catalyst Pharmaceutical seller in Q2 2018 was Great Point Partners, an estimated $6.44M sold.
Based on aggregated 13F filings for Q2 2018.